143 related articles for article (PubMed ID: 38056572)
1. Rapid ART initiation with bictegravir/emtricitabine/tenofovir alafenamide in individuals presenting with advanced HIV disease (Rainbow study).
Camici M; Gagliardini R; Lanini S; Del Duca G; Mondi A; Ottou S; Plazzi MM; De Zottis F; Pinnetti C; Vergori A; Grilli E; Mastrorosa I; Mazzotta V; Paulicelli J; Bellagamba R; Cimini E; Tartaglia E; Notari S; Tempestilli M; Cicalini S; Amendola A; Abbate I; Forbici F; Fabeni L; Girardi E; Vaia F; Maggi F; Antinori A
Int J Antimicrob Agents; 2024 Jan; 63(1):107049. PubMed ID: 38056572
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort.
d'Arminio Monforte A; Tavelli A; Di Biagio A; Sarmati L; Marchetti GC; Bai F; Cingolani A; Quiros Roldan E; Mussini C; Lichtner M; Vergori A; Piconi S; Orofino G; Fusco FM; Bandera A; Nozza S; Castagna A; Antinori A;
J Antimicrob Chemother; 2024 Jun; 79(6):1279-1288. PubMed ID: 38581349
[TBL] [Abstract][Full Text] [Related]
3. Bictegravir/emtricitabine/tenofovir alafenamide as first-line treatment in naïve HIV patients in a rapid-initiation model of care: BIC-NOW clinical trial.
Hidalgo-Tenorio C; Sequera S; Vivancos MJ; Vinuesa D; Collado A; Santos IL; Sorni P; Cabello-Clotet N; Montero M; Font CR; Terron A; Galindo MJ; Martinez O; Ryan P; Omar-Mohamed M; Albendín-Iglesias H; Javier R; Ruz MÁL; Romero A; Garcia-Vallecillos C
Int J Antimicrob Agents; 2024 Jun; 63(6):107164. PubMed ID: 38574873
[TBL] [Abstract][Full Text] [Related]
4. Brief Report: Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials.
Orkin C; Ajana F; Kityo C; Koenig E; Natukunda E; Gandhi-Patel B; Wang H; Liu Y; Wei X; White K; Makadzange T; Pikora C; McNicholl I; Collins SE; Brainard D; Chuck SK
J Acquir Immune Defic Syndr; 2021 Dec; 88(4):393-398. PubMed ID: 34506342
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in HIV late presenters.
Corona D; Pérez-Valero I; Camacho A; Gutiérrez Liarte Á; Montero-Alonso M; Alemán MR; Ruiz-Seco P; Pérez González A; Riera M; Jarrin I; Rivero-Juárez A; Rivero A
Int J Antimicrob Agents; 2024 Jan; 63(1):107016. PubMed ID: 37890734
[TBL] [Abstract][Full Text] [Related]
6. Bictegravir/emtricitabine/tenofovir alafenamide in paediatrics: Real-life experience from a French cohort (2019-2023).
Frange P; Veber F; Burgard M; Blanche S; Avettand-Fenoel V
HIV Med; 2024 Feb; 25(2):299-305. PubMed ID: 37807595
[TBL] [Abstract][Full Text] [Related]
7. Safety and adherence of bictegravir/emtricitabine/tenofovir alafenamide for HIV post-exposure prophylaxis among adults in Guiyang China: a prospective cohort study.
Gan L; Xie X; Fu Y; Yang X; Ma S; Kong L; Song C; Song Y; Ren T; Long H
BMC Infect Dis; 2024 Jun; 24(1):565. PubMed ID: 38844855
[TBL] [Abstract][Full Text] [Related]
8. Comparing the efficacy and safety of a first-line regimen with emtricitabine/tenofovir alafenamide fumarate plus either bictegravir or dolutegravir: Results from clinical practice.
Ciccullo A; Baldin G; Borghi V; Oreni L; Lagi F; Fusco P; Giacomelli A; Torti C; Sterrantino G; Mussini C; Antinori S; Di Giambenedetto S
Int J Antimicrob Agents; 2024 Jan; 63(1):107040. PubMed ID: 37981074
[TBL] [Abstract][Full Text] [Related]
9. Same-day initiation of bictegravir/emtricitabine/tenofovir alafenamide: Week 48 results of the FAST study-IMEA 055.
Bachelard A; Isernia V; Charpentier C; Benalycherif A; Mora M; Donadille C; Duvivier C; Lacombe K; El Mouhebb M; Spire B; Landman R; Descamps D; Peytavin G; Assoumou L; Ghosn J;
J Antimicrob Chemother; 2023 Mar; 78(3):769-778. PubMed ID: 36659824
[TBL] [Abstract][Full Text] [Related]
10. Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study.
Hagins D; Kumar P; Saag M; Wurapa AK; Brar I; Berger D; Osiyemi O; Hileman CO; Ramgopal MN; McDonald C; Blair C; Andreatta K; Collins SE; Brainard DM; Martin H;
J Acquir Immune Defic Syndr; 2021 Sep; 88(1):86-95. PubMed ID: 34397746
[TBL] [Abstract][Full Text] [Related]
11. Twelve-month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: Real-world insights from BICSTaR cohorts.
Esser S; Brunetta J; Inciarte A; Levy I; D'Arminio Monforte A; Lambert JS; van Welzen B; Teruya K; Boffito M; Liu CE; Altuntas Aydın O; Thorpe D; Heinzkill M; Marongiu A; Cassidy T; Haubrich R; D'Amato L; Robineau O
HIV Med; 2024 Apr; 25(4):440-453. PubMed ID: 38148567
[TBL] [Abstract][Full Text] [Related]
12. Integrase strand transfer inhibitor resistance mediated by R263K plus E157Q in a patient with HIV infection treated with bictegravir/tenofovir alafenamide/emtricitabine: case report and review of the literature.
Buzon-Martin L; Navarro-San Francisco C; Fernandez-Regueras M; Sanchez-Gomez L
J Antimicrob Chemother; 2024 May; 79(5):1153-1156. PubMed ID: 38558010
[TBL] [Abstract][Full Text] [Related]
13. Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial.
Mills AM; Rizzardini G; Ramgopal MN; Osiyemi OO; Bogner JR; Hagins DP; Paredes R; Reynes J; Rockstroh JK; Carr A; Su FH; Klopfer SO; Eves K; Plank RM; Correll T; Fox MC
Lancet HIV; 2024 Jun; 11(6):e357-e368. PubMed ID: 38734016
[TBL] [Abstract][Full Text] [Related]
14. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Gallant J; Lazzarin A; Mills A; Orkin C; Podzamczer D; Tebas P; Girard PM; Brar I; Daar ES; Wohl D; Rockstroh J; Wei X; Custodio J; White K; Martin H; Cheng A; Quirk E
Lancet; 2017 Nov; 390(10107):2063-2072. PubMed ID: 28867497
[TBL] [Abstract][Full Text] [Related]
15. Increased viral load in a hospitalized patient on treatment with crushed bictegravir/emtricitabine/tenofovir alafenamide: A case report and review of the literature.
Rowe SM; Clary JC; Drummond M; Derrick C; Sanasi K; Bookstaver PB
Am J Health Syst Pharm; 2022 Aug; 79(16):1330-1336. PubMed ID: 35511892
[TBL] [Abstract][Full Text] [Related]
16. Twelve-month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV from the Canadian cohort of the observational BICSTaR study.
Wong A; Brunetta J; De Wet J; Logue K; Loemba H; Saifi T; Mumm D; Marongiu A; Harrison R; Thorpe D; Trottier B
Medicine (Baltimore); 2024 Apr; 103(16):e37785. PubMed ID: 38640301
[TBL] [Abstract][Full Text] [Related]
17. Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
Wohl DA; Yazdanpanah Y; Baumgarten A; Clarke A; Thompson MA; Brinson C; Hagins D; Ramgopal MN; Antinori A; Wei X; Acosta R; Collins SE; Brainard D; Martin H
Lancet HIV; 2019 Jun; 6(6):e355-e363. PubMed ID: 31068270
[TBL] [Abstract][Full Text] [Related]
18. Body mass index increase and weight gain among people living with HIV-1 initiated on single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide in the United States.
Emond B; Rossi C; Côté-Sergent A; Bookhart B; Anderson D; Lefebvre P; Lafeuille MH; Donga P
Curr Med Res Opin; 2022 Feb; 38(2):287-298. PubMed ID: 34812097
[TBL] [Abstract][Full Text] [Related]
19. Real-life data of immune recovery using bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people living with HIV. Results at 48-96 weeks of RETROBIC Study.
Troya J; Pousada G; Micán R; Galera C; Sanz J; de Los Santos I; Dueñas C; Cabello N; Martín C; Galindo MJ; Garcinuño MÁ; Pedrero-Tomé R; Buzón L
J Antimicrob Chemother; 2024 Mar; 79(3):595-607. PubMed ID: 38267266
[TBL] [Abstract][Full Text] [Related]
20. Short-course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir/emtricitabine/tenofovir alafenamide.
Liou BH; Cheng CN; Lin YT; Lin YJ; Chuang YC; Lin KY; Liu WC; Lin SW; Kuo CH; Sun HY; Hung CC
J Int AIDS Soc; 2021 Nov; 24(11):e25844. PubMed ID: 34822220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
